Which dyskinesia scale best detects treatment response?
Identifieur interne : 002694 ( Istex/Corpus ); précédent : 002693; suivant : 002695Which dyskinesia scale best detects treatment response?
Auteurs : Christopher G. Goetz ; Glenn T. Stebbins ; Kathryn A. Chung ; Robert A. Hauser ; Janis M. Miyasaki ; Anthony P. Nicholas ; Werner Poewe ; Klaus Seppi ; Olivier Rascol ; Mark A. Stacy ; John G. Nutt ; Caroline M. Tanner ; Alison Urkowitz ; Jean A. Jaglin ; Song GeSource :
- Movement Disorders [ 0885-3185 ] ; 2013-03.
Abstract
Numerous scales assess dyskinesia in Parkinson's disease (PD), variably focusing on anatomical distribution, phenomenology, time, severity, and disability. No study has compared these scales and their relative ability to detect change related to an established treatment. We conducted a randomized placebo‐controlled trial of amantadine, assessing dyskinesia at baseline and at 4 and 8 weeks using the following scales: Unified Dyskinesia Rating Scale (UDysRS), Lang‐Fahn Activities of Daily Living Dyskinesia Rating Scale (LF), 26‐Item Parkinson's Disease Dyskinesia scale (PDD‐26), patient diaries, modified Abnormal Involuntary Movements Scale (AIMS), Rush Dyskinesia Rating Scale (RDRS), dyskinesia items from the Movement Disorder Society–sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS), and Clinical Global Impression (severity and change: CGI‐S, CGI‐C). Scale order was randomized at each visit, but raters were aware of each scale as it was administered. Sensitivity to treatment was assessed using effect size. Sixty‐one randomized dyskinetic PD subjects (31 amantadine, 30 placebo) completed the study. Four of the 8 scales (CGI‐C, LF, PDD‐26, and UDysRS) detected a significant treatment. The UDysRS Total Score showed the highest effect size (η2 = 0.138) for detecting treatment‐related change, with all other scales having effect sizes < 0.1. No scale was resistant to placebo effects. This study resolves 2 major issues useful for future testing of new antidyskinesia treatments: among tested scales, the UDysRS, having both subjective and objective dyskinesia ratings, is superior for detecting treatment effects; and the magnitude of the UDysRS effect size from amantadine sets a clear standard for comparison for new agents. © 2012 Movement Disorder Society
Url:
DOI: 10.1002/mds.25321
Links to Exploration step
ISTEX:8C074267DAD4F0BE4E25A0574ABEF5255353838FLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Which dyskinesia scale best detects treatment response?</title><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Illinois, Chicago, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: cgoetz@rush.edu</mods:affiliation></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Illinois, Chicago, USA</mods:affiliation></affiliation></author><author><name sortKey="Chung, Kathryn A" sort="Chung, Kathryn A" uniqKey="Chung K" first="Kathryn A." last="Chung">Kathryn A. Chung</name><affiliation><mods:affiliation>Department of Neurology, Oregon Health Sciences University and Portland VA Medical Center, Oregon, Portland, USA</mods:affiliation></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Florida, Tampa, USA</mods:affiliation></affiliation></author><author><name sortKey="Miyasaki, Janis M" sort="Miyasaki, Janis M" uniqKey="Miyasaki J" first="Janis M." last="Miyasaki">Janis M. Miyasaki</name><affiliation><mods:affiliation>The Edmond J. Safra Program in Parkinson's Disease, University of Toronto, Ontario, Toronto, Canada</mods:affiliation></affiliation></author><author><name sortKey="Nicholas, Anthony P" sort="Nicholas, Anthony P" uniqKey="Nicholas A" first="Anthony P." last="Nicholas">Anthony P. Nicholas</name><affiliation><mods:affiliation>Department of Neurology, University of Alabama and Birmingham VA Medical Center, Alabama, Birmingham, USA</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name><affiliation><mods:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Clinical Investigation Center CIC9302 and Departments of Clinical Pharmacology and Neuroscience, INSERM, University Hospital of Toulouse and University of Toulouse III, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Stacy, Mark A" sort="Stacy, Mark A" uniqKey="Stacy M" first="Mark A." last="Stacy">Mark A. Stacy</name><affiliation><mods:affiliation>Department of Neurology, Duke University, North Carolina, Durham, USA</mods:affiliation></affiliation></author><author><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G." last="Nutt">John G. Nutt</name><affiliation><mods:affiliation>Department of Neurology, Oregon Health Sciences University and Portland VA Medical Center, Oregon, Portland, USA</mods:affiliation></affiliation></author><author><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M." last="Tanner">Caroline M. Tanner</name><affiliation><mods:affiliation>Parkinson's Institute and Clinical Center, California, Sunnyvale, USA</mods:affiliation></affiliation></author><author><name sortKey="Urkowitz, Alison" sort="Urkowitz, Alison" uniqKey="Urkowitz A" first="Alison" last="Urkowitz">Alison Urkowitz</name><affiliation><mods:affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, New York City, USA</mods:affiliation></affiliation></author><author><name sortKey="Jaglin, Jean A" sort="Jaglin, Jean A" uniqKey="Jaglin J" first="Jean A." last="Jaglin">Jean A. Jaglin</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Illinois, Chicago, USA</mods:affiliation></affiliation></author><author><name sortKey="Ge, Song" sort="Ge, Song" uniqKey="Ge S" first="Song" last="Ge">Song Ge</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Illinois, Chicago, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:8C074267DAD4F0BE4E25A0574ABEF5255353838F</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1002/mds.25321</idno><idno type="url">https://api-v5.istex.fr/document/8C074267DAD4F0BE4E25A0574ABEF5255353838F/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002694</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002694</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Which dyskinesia scale best detects treatment response?</title><author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Illinois, Chicago, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: cgoetz@rush.edu</mods:affiliation></affiliation></author><author><name sortKey="Stebbins, Glenn T" sort="Stebbins, Glenn T" uniqKey="Stebbins G" first="Glenn T." last="Stebbins">Glenn T. Stebbins</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Illinois, Chicago, USA</mods:affiliation></affiliation></author><author><name sortKey="Chung, Kathryn A" sort="Chung, Kathryn A" uniqKey="Chung K" first="Kathryn A." last="Chung">Kathryn A. Chung</name><affiliation><mods:affiliation>Department of Neurology, Oregon Health Sciences University and Portland VA Medical Center, Oregon, Portland, USA</mods:affiliation></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation><mods:affiliation>Department of Neurology, University of South Florida, Florida, Tampa, USA</mods:affiliation></affiliation></author><author><name sortKey="Miyasaki, Janis M" sort="Miyasaki, Janis M" uniqKey="Miyasaki J" first="Janis M." last="Miyasaki">Janis M. Miyasaki</name><affiliation><mods:affiliation>The Edmond J. Safra Program in Parkinson's Disease, University of Toronto, Ontario, Toronto, Canada</mods:affiliation></affiliation></author><author><name sortKey="Nicholas, Anthony P" sort="Nicholas, Anthony P" uniqKey="Nicholas A" first="Anthony P." last="Nicholas">Anthony P. Nicholas</name><affiliation><mods:affiliation>Department of Neurology, University of Alabama and Birmingham VA Medical Center, Alabama, Birmingham, USA</mods:affiliation></affiliation></author><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation><mods:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name><affiliation><mods:affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Clinical Investigation Center CIC9302 and Departments of Clinical Pharmacology and Neuroscience, INSERM, University Hospital of Toulouse and University of Toulouse III, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Stacy, Mark A" sort="Stacy, Mark A" uniqKey="Stacy M" first="Mark A." last="Stacy">Mark A. Stacy</name><affiliation><mods:affiliation>Department of Neurology, Duke University, North Carolina, Durham, USA</mods:affiliation></affiliation></author><author><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G." last="Nutt">John G. Nutt</name><affiliation><mods:affiliation>Department of Neurology, Oregon Health Sciences University and Portland VA Medical Center, Oregon, Portland, USA</mods:affiliation></affiliation></author><author><name sortKey="Tanner, Caroline M" sort="Tanner, Caroline M" uniqKey="Tanner C" first="Caroline M." last="Tanner">Caroline M. Tanner</name><affiliation><mods:affiliation>Parkinson's Institute and Clinical Center, California, Sunnyvale, USA</mods:affiliation></affiliation></author><author><name sortKey="Urkowitz, Alison" sort="Urkowitz, Alison" uniqKey="Urkowitz A" first="Alison" last="Urkowitz">Alison Urkowitz</name><affiliation><mods:affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, New York City, USA</mods:affiliation></affiliation></author><author><name sortKey="Jaglin, Jean A" sort="Jaglin, Jean A" uniqKey="Jaglin J" first="Jean A." last="Jaglin">Jean A. Jaglin</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Illinois, Chicago, USA</mods:affiliation></affiliation></author><author><name sortKey="Ge, Song" sort="Ge, Song" uniqKey="Ge S" first="Song" last="Ge">Song Ge</name><affiliation><mods:affiliation>Department of Neurological Sciences, Rush University Medical Center, Illinois, Chicago, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><date type="published" when="2013-03">2013-03</date><biblScope unit="volume">28</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="341">341</biblScope><biblScope unit="page" to="346">346</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">8C074267DAD4F0BE4E25A0574ABEF5255353838F</idno><idno type="DOI">10.1002/mds.25321</idno><idno type="ArticleID">MDS25321</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Numerous scales assess dyskinesia in Parkinson's disease (PD), variably focusing on anatomical distribution, phenomenology, time, severity, and disability. No study has compared these scales and their relative ability to detect change related to an established treatment. We conducted a randomized placebo‐controlled trial of amantadine, assessing dyskinesia at baseline and at 4 and 8 weeks using the following scales: Unified Dyskinesia Rating Scale (UDysRS), Lang‐Fahn Activities of Daily Living Dyskinesia Rating Scale (LF), 26‐Item Parkinson's Disease Dyskinesia scale (PDD‐26), patient diaries, modified Abnormal Involuntary Movements Scale (AIMS), Rush Dyskinesia Rating Scale (RDRS), dyskinesia items from the Movement Disorder Society–sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS), and Clinical Global Impression (severity and change: CGI‐S, CGI‐C). Scale order was randomized at each visit, but raters were aware of each scale as it was administered. Sensitivity to treatment was assessed using effect size. Sixty‐one randomized dyskinetic PD subjects (31 amantadine, 30 placebo) completed the study. Four of the 8 scales (CGI‐C, LF, PDD‐26, and UDysRS) detected a significant treatment. The UDysRS Total Score showed the highest effect size (η2 = 0.138) for detecting treatment‐related change, with all other scales having effect sizes < 0.1. No scale was resistant to placebo effects. This study resolves 2 major issues useful for future testing of new antidyskinesia treatments: among tested scales, the UDysRS, having both subjective and objective dyskinesia ratings, is superior for detecting treatment effects; and the magnitude of the UDysRS effect size from amantadine sets a clear standard for comparison for new agents. © 2012 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Christopher G. Goetz MD</name><affiliations><json:string>Department of Neurological Sciences, Rush University Medical Center, Illinois, Chicago, USA</json:string><json:string>E-mail: cgoetz@rush.edu</json:string></affiliations></json:item><json:item><name>Glenn T. Stebbins PhD</name><affiliations><json:string>Department of Neurological Sciences, Rush University Medical Center, Illinois, Chicago, USA</json:string></affiliations></json:item><json:item><name>Kathryn A. Chung MD</name><affiliations><json:string>Department of Neurology, Oregon Health Sciences University and Portland VA Medical Center, Oregon, Portland, USA</json:string></affiliations></json:item><json:item><name>Robert A. Hauser MD, MBA</name><affiliations><json:string>Department of Neurology, University of South Florida, Florida, Tampa, USA</json:string></affiliations></json:item><json:item><name>Janis M. Miyasaki MD</name><affiliations><json:string>The Edmond J. Safra Program in Parkinson's Disease, University of Toronto, Ontario, Toronto, Canada</json:string></affiliations></json:item><json:item><name>Anthony P. Nicholas MD, PhD</name><affiliations><json:string>Department of Neurology, University of Alabama and Birmingham VA Medical Center, Alabama, Birmingham, USA</json:string></affiliations></json:item><json:item><name>Werner Poewe MD</name><affiliations><json:string>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Klaus Seppi MD</name><affiliations><json:string>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</json:string></affiliations></json:item><json:item><name>Olivier Rascol MD, PhD</name><affiliations><json:string>Clinical Investigation Center CIC9302 and Departments of Clinical Pharmacology and Neuroscience, INSERM, University Hospital of Toulouse and University of Toulouse III, Toulouse, France</json:string></affiliations></json:item><json:item><name>Mark A. Stacy MD</name><affiliations><json:string>Department of Neurology, Duke University, North Carolina, Durham, USA</json:string></affiliations></json:item><json:item><name>John G. Nutt MD</name><affiliations><json:string>Department of Neurology, Oregon Health Sciences University and Portland VA Medical Center, Oregon, Portland, USA</json:string></affiliations></json:item><json:item><name>Caroline M. Tanner MD, PhD</name><affiliations><json:string>Parkinson's Institute and Clinical Center, California, Sunnyvale, USA</json:string></affiliations></json:item><json:item><name>Alison Urkowitz MPA</name><affiliations><json:string>Michael J. Fox Foundation for Parkinson's Research, New York, New York City, USA</json:string></affiliations></json:item><json:item><name>Jean A. Jaglin RN</name><affiliations><json:string>Department of Neurological Sciences, Rush University Medical Center, Illinois, Chicago, USA</json:string></affiliations></json:item><json:item><name>Song Ge MS</name><affiliations><json:string>Department of Neurological Sciences, Rush University Medical Center, Illinois, Chicago, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>dyskinesia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>rating scales</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>clinimetrics</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>amantadine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>clinical trials</value></json:item></subject><articleId><json:string>MDS25321</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Numerous scales assess dyskinesia in Parkinson's disease (PD), variably focusing on anatomical distribution, phenomenology, time, severity, and disability. No study has compared these scales and their relative ability to detect change related to an established treatment. We conducted a randomized placebo‐controlled trial of amantadine, assessing dyskinesia at baseline and at 4 and 8 weeks using the following scales: Unified Dyskinesia Rating Scale (UDysRS), Lang‐Fahn Activities of Daily Living Dyskinesia Rating Scale (LF), 26‐Item Parkinson's Disease Dyskinesia scale (PDD‐26), patient diaries, modified Abnormal Involuntary Movements Scale (AIMS), Rush Dyskinesia Rating Scale (RDRS), dyskinesia items from the Movement Disorder Society–sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS), and Clinical Global Impression (severity and change: CGI‐S, CGI‐C). Scale order was randomized at each visit, but raters were aware of each scale as it was administered. Sensitivity to treatment was assessed using effect size. Sixty‐one randomized dyskinetic PD subjects (31 amantadine, 30 placebo) completed the study. Four of the 8 scales (CGI‐C, LF, PDD‐26, and UDysRS) detected a significant treatment. The UDysRS Total Score showed the highest effect size (η2 = 0.138) for detecting treatment‐related change, with all other scales having effect sizes > 0.1. No scale was resistant to placebo effects. This study resolves 2 major issues useful for future testing of new antidyskinesia treatments: among tested scales, the UDysRS, having both subjective and objective dyskinesia ratings, is superior for detecting treatment effects; and the magnitude of the UDysRS effect size from amantadine sets a clear standard for comparison for new agents. © 2012 Movement Disorder Society</abstract><qualityIndicators><score>7.249</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 809.972 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1805</abstractCharCount><pdfWordCount>4249</pdfWordCount><pdfCharCount>27713</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>256</abstractWordCount></qualityIndicators><title>Which dyskinesia scale best detects treatment response?</title><genre><json:string>article</json:string></genre><host><title>Movement Disorders</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi><issn><json:string>0885-3185</json:string></issn><eissn><json:string>1531-8257</json:string></eissn><publisherId><json:string>MDS</json:string></publisherId><volume>28</volume><issue>3</issue><pages><first>341</first><last>346</last><total>6</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Research Article</value></json:item></subject></host><categories><wos><json:string>science</json:string><json:string>clinical neurology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix></categories><publicationDate>2013</publicationDate><copyrightDate>2013</copyrightDate><doi><json:string>10.1002/mds.25321</json:string></doi><id>8C074267DAD4F0BE4E25A0574ABEF5255353838F</id><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api-v5.istex.fr/document/8C074267DAD4F0BE4E25A0574ABEF5255353838F/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api-v5.istex.fr/document/8C074267DAD4F0BE4E25A0574ABEF5255353838F/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api-v5.istex.fr/document/8C074267DAD4F0BE4E25A0574ABEF5255353838F/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Which dyskinesia scale best detects treatment response?</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><availability><p>Copyright © 2012 Movement Disorder SocietyCopyright © 2012 Movement Disorder Society</p></availability><date>2012-12-04</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Which dyskinesia scale best detects treatment response?</title><author xml:id="author-1"><persName><forename type="first">Christopher G.</forename><surname>Goetz</surname></persName><roleName type="degree">MD</roleName><email>cgoetz@rush.edu</email><affiliation>Department of Neurological Sciences, Rush University Medical Center, Illinois, Chicago, USA</affiliation></author><author xml:id="author-2"><persName><forename type="first">Glenn T.</forename><surname>Stebbins</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Neurological Sciences, Rush University Medical Center, Illinois, Chicago, USA</affiliation></author><author xml:id="author-3"><persName><forename type="first">Kathryn A.</forename><surname>Chung</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Oregon Health Sciences University and Portland VA Medical Center, Oregon, Portland, USA</affiliation></author><author xml:id="author-4"><persName><forename type="first">Robert A.</forename><surname>Hauser</surname></persName><roleName type="degree">MD, MBA</roleName><affiliation>Department of Neurology, University of South Florida, Florida, Tampa, USA</affiliation></author><author xml:id="author-5"><persName><forename type="first">Janis M.</forename><surname>Miyasaki</surname></persName><roleName type="degree">MD</roleName><affiliation>The Edmond J. Safra Program in Parkinson's Disease, University of Toronto, Ontario, Toronto, Canada</affiliation></author><author xml:id="author-6"><persName><forename type="first">Anthony P.</forename><surname>Nicholas</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Department of Neurology, University of Alabama and Birmingham VA Medical Center, Alabama, Birmingham, USA</affiliation></author><author xml:id="author-7"><persName><forename type="first">Werner</forename><surname>Poewe</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</affiliation></author><author xml:id="author-8"><persName><forename type="first">Klaus</forename><surname>Seppi</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</affiliation></author><author xml:id="author-9"><persName><forename type="first">Olivier</forename><surname>Rascol</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Clinical Investigation Center CIC9302 and Departments of Clinical Pharmacology and Neuroscience, INSERM, University Hospital of Toulouse and University of Toulouse III, Toulouse, France</affiliation></author><author xml:id="author-10"><persName><forename type="first">Mark A.</forename><surname>Stacy</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Duke University, North Carolina, Durham, USA</affiliation></author><author xml:id="author-11"><persName><forename type="first">John G.</forename><surname>Nutt</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurology, Oregon Health Sciences University and Portland VA Medical Center, Oregon, Portland, USA</affiliation></author><author xml:id="author-12"><persName><forename type="first">Caroline M.</forename><surname>Tanner</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>Parkinson's Institute and Clinical Center, California, Sunnyvale, USA</affiliation></author><author xml:id="author-13"><persName><forename type="first">Alison</forename><surname>Urkowitz</surname></persName><roleName type="degree">MPA</roleName><affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, New York City, USA</affiliation></author><author xml:id="author-14"><persName><forename type="first">Jean A.</forename><surname>Jaglin</surname></persName><roleName type="degree">RN</roleName><affiliation>Department of Neurological Sciences, Rush University Medical Center, Illinois, Chicago, USA</affiliation></author><author xml:id="author-15"><persName><forename type="first">Song</forename><surname>Ge</surname></persName><roleName type="degree">MS</roleName><affiliation>Department of Neurological Sciences, Rush University Medical Center, Illinois, Chicago, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><date type="published" when="2013-03"></date><biblScope unit="volume">28</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="341">341</biblScope><biblScope unit="page" to="346">346</biblScope></imprint></monogr><idno type="istex">8C074267DAD4F0BE4E25A0574ABEF5255353838F</idno><idno type="DOI">10.1002/mds.25321</idno><idno type="ArticleID">MDS25321</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2012-12-04</date></creation><langUsage><language ident="en">en</language></langUsage><abstract><p>Numerous scales assess dyskinesia in Parkinson's disease (PD), variably focusing on anatomical distribution, phenomenology, time, severity, and disability. No study has compared these scales and their relative ability to detect change related to an established treatment. We conducted a randomized placebo‐controlled trial of amantadine, assessing dyskinesia at baseline and at 4 and 8 weeks using the following scales: Unified Dyskinesia Rating Scale (UDysRS), Lang‐Fahn Activities of Daily Living Dyskinesia Rating Scale (LF), 26‐Item Parkinson's Disease Dyskinesia scale (PDD‐26), patient diaries, modified Abnormal Involuntary Movements Scale (AIMS), Rush Dyskinesia Rating Scale (RDRS), dyskinesia items from the Movement Disorder Society–sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS), and Clinical Global Impression (severity and change: CGI‐S, CGI‐C). Scale order was randomized at each visit, but raters were aware of each scale as it was administered. Sensitivity to treatment was assessed using effect size. Sixty‐one randomized dyskinetic PD subjects (31 amantadine, 30 placebo) completed the study. Four of the 8 scales (CGI‐C, LF, PDD‐26, and UDysRS) detected a significant treatment. The UDysRS Total Score showed the highest effect size (η2 = 0.138) for detecting treatment‐related change, with all other scales having effect sizes < 0.1. No scale was resistant to placebo effects. This study resolves 2 major issues useful for future testing of new antidyskinesia treatments: among tested scales, the UDysRS, having both subjective and objective dyskinesia ratings, is superior for detecting treatment effects; and the magnitude of the UDysRS effect size from amantadine sets a clear standard for comparison for new agents. © 2012 Movement Disorder Society</p></abstract><textClass><keywords scheme="keyword"><list><head>keywords</head><item><term>dyskinesia</term></item><item><term>Parkinson's disease</term></item><item><term>rating scales</term></item><item><term>clinimetrics</term></item><item><term>amantadine</term></item><item><term>clinical trials</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article-category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2012-09-04">Received</change><change when="2012-11-15">Registration</change><change when="2012-12-04">Created</change><change when="2013-03">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api-v5.istex.fr/document/8C074267DAD4F0BE4E25A0574ABEF5255353838F/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en" xml:id="mds25321"><header><publicationMeta level="product"><doi origin="wiley" registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="30"><doi>10.1002/mds.v28.3</doi><copyright ownership="publisher">Copyright © 2012 Movement Disorder Society</copyright><numberingGroup><numbering type="journalVolume" number="28">28</numbering><numbering type="journalIssue">3</numbering></numberingGroup><coverDate startDate="2013-03">March 2013</coverDate></publicationMeta><publicationMeta level="unit" position="200" type="article" status="forIssue"><doi>10.1002/mds.25321</doi><idGroup><id type="unit" value="MDS25321"></id></idGroup><countGroup><count type="pageTotal" number="6"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="publisher">Copyright © 2012 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2012-09-04"></event><event type="manuscriptRevised" date="2012-11-08"></event><event type="manuscriptAccepted" date="2012-11-15"></event><event type="xmlCreated" agent="Cenveo Publisher Services" date="2012-12-04"></event><event type="publishedOnlineEarlyUnpaginated" date="2013-02-06"></event><event type="publishedOnlineFinalForm" date="2013-03-21"></event><event type="firstOnline" date="2013-02-06"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.6.4 mode:FullText" date="2015-10-02"></event></eventGroup><numberingGroup><numbering type="pageFirst">341</numbering><numbering type="pageLast">346</numbering></numberingGroup><correspondenceTo><b>Correspondence to:</b> Dr. Christopher Goetz, Rush‐Presbyterian‐St. Luke's Medical Center, Suite 755, 1725 W. Harrison Street, Chicago, IL 60612, USA; <email>cgoetz@rush.edu</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS25321.pdf"></link></linkGroup></publicationMeta><contentMeta><titleGroup><title type="main">Which dyskinesia scale best detects treatment response?</title><title type="short">Dyskinesia Scale Detecting Treatment Response</title><title type="shortAuthors">Goetz et al</title></titleGroup><creators><creator affiliationRef="#mds25321-aff-0001" corresponding="yes" creatorRole="author" xml:id="mds25321-cr-0001"><personName><givenNames>Christopher G.</givenNames><familyName>Goetz</familyName><degrees>MD</degrees></personName></creator><creator affiliationRef="#mds25321-aff-0001" creatorRole="author" xml:id="mds25321-cr-0002"><personName><givenNames>Glenn T.</givenNames><familyName>Stebbins</familyName><degrees>PhD</degrees></personName></creator><creator affiliationRef="#mds25321-aff-0002" creatorRole="author" xml:id="mds25321-cr-0003"><personName><givenNames>Kathryn A.</givenNames><familyName>Chung</familyName><degrees>MD</degrees></personName></creator><creator affiliationRef="#mds25321-aff-0003" creatorRole="author" xml:id="mds25321-cr-0004"><personName><givenNames>Robert A.</givenNames><familyName>Hauser</familyName><degrees>MD, MBA</degrees></personName></creator><creator affiliationRef="#mds25321-aff-0004" creatorRole="author" xml:id="mds25321-cr-0005"><personName><givenNames>Janis M.</givenNames><familyName>Miyasaki</familyName><degrees>MD</degrees></personName></creator><creator affiliationRef="#mds25321-aff-0005" creatorRole="author" xml:id="mds25321-cr-0006"><personName><givenNames>Anthony P.</givenNames><familyName>Nicholas</familyName><degrees>MD, PhD</degrees></personName></creator><creator affiliationRef="#mds25321-aff-0006" creatorRole="author" xml:id="mds25321-cr-0007"><personName><givenNames>Werner</givenNames><familyName>Poewe</familyName><degrees>MD</degrees></personName></creator><creator affiliationRef="#mds25321-aff-0006" creatorRole="author" xml:id="mds25321-cr-0008"><personName><givenNames>Klaus</givenNames><familyName>Seppi</familyName><degrees>MD</degrees></personName></creator><creator affiliationRef="#mds25321-aff-0007" creatorRole="author" xml:id="mds25321-cr-0009"><personName><givenNames>Olivier</givenNames><familyName>Rascol</familyName><degrees>MD, PhD</degrees></personName></creator><creator affiliationRef="#mds25321-aff-0008" creatorRole="author" xml:id="mds25321-cr-0010"><personName><givenNames>Mark A.</givenNames><familyName>Stacy</familyName><degrees>MD</degrees></personName></creator><creator affiliationRef="#mds25321-aff-0002" creatorRole="author" xml:id="mds25321-cr-0011"><personName><givenNames>John G.</givenNames><familyName>Nutt</familyName><degrees>MD</degrees></personName></creator><creator affiliationRef="#mds25321-aff-0009" creatorRole="author" xml:id="mds25321-cr-0012"><personName><givenNames>Caroline M.</givenNames><familyName>Tanner</familyName><degrees>MD, PhD</degrees></personName></creator><creator affiliationRef="#mds25321-aff-0010" creatorRole="author" xml:id="mds25321-cr-0013"><personName><givenNames>Alison</givenNames><familyName>Urkowitz</familyName><degrees>MPA</degrees></personName></creator><creator affiliationRef="#mds25321-aff-0001" creatorRole="author" xml:id="mds25321-cr-0014"><personName><givenNames>Jean A.</givenNames><familyName>Jaglin</familyName><degrees>RN</degrees></personName></creator><creator affiliationRef="#mds25321-aff-0001" creatorRole="author" xml:id="mds25321-cr-0015"><personName><givenNames>Song</givenNames><familyName>Ge</familyName><degrees>MS</degrees></personName></creator></creators><affiliationGroup><affiliation countryCode="US" type="organization" xml:id="mds25321-aff-0001"><orgDiv>Department of Neurological Sciences</orgDiv><orgName>Rush University Medical Center</orgName><address><city>Chicago</city><countryPart>Illinois</countryPart><country>USA</country></address></affiliation><affiliation countryCode="US" type="organization" xml:id="mds25321-aff-0002"><orgDiv>Department of Neurology</orgDiv><orgName>Oregon Health Sciences University and Portland VA Medical Center</orgName><address><city>Portland</city><countryPart>Oregon</countryPart><country>USA</country></address></affiliation><affiliation countryCode="US" type="organization" xml:id="mds25321-aff-0003"><orgDiv>Department of Neurology</orgDiv><orgName>University of South Florida</orgName><address><city>Tampa</city><countryPart>Florida</countryPart><country>USA</country></address></affiliation><affiliation countryCode="CA" type="organization" xml:id="mds25321-aff-0004"><orgDiv>The Edmond J. Safra Program in Parkinson's Disease</orgDiv><orgName>University of Toronto</orgName><address><city>Toronto</city><countryPart>Ontario</countryPart><country>Canada</country></address></affiliation><affiliation countryCode="US" type="organization" xml:id="mds25321-aff-0005"><orgDiv>Department of Neurology</orgDiv><orgName>University of Alabama and Birmingham VA Medical Center</orgName><address><city>Birmingham</city><countryPart>Alabama</countryPart><country>USA</country></address></affiliation><affiliation countryCode="AT" type="organization" xml:id="mds25321-aff-0006"><orgDiv>Department of Neurology</orgDiv><orgName>Innsbruck Medical University</orgName><address><city>Innsbruck</city><country>Austria</country></address></affiliation><affiliation countryCode="FR" type="organization" xml:id="mds25321-aff-0007"><orgDiv>Clinical Investigation Center CIC9302 and Departments of Clinical Pharmacology and Neuroscience, INSERM</orgDiv><orgName>University Hospital of Toulouse and University of Toulouse III</orgName><address><city>Toulouse</city><country>France</country></address></affiliation><affiliation countryCode="US" type="organization" xml:id="mds25321-aff-0008"><orgDiv>Department of Neurology</orgDiv><orgName>Duke University</orgName><address><city>Durham</city><countryPart>North Carolina</countryPart><country>USA</country></address></affiliation><affiliation countryCode="US" type="organization" xml:id="mds25321-aff-0009"><orgName>Parkinson's Institute and Clinical Center</orgName><address><city>Sunnyvale</city><countryPart>California</countryPart><country>USA</country></address></affiliation><affiliation countryCode="US" type="organization" xml:id="mds25321-aff-0010"><orgName>Michael J. Fox Foundation for Parkinson's Research</orgName><address><city>New York City</city><countryPart>New York</countryPart><country>USA</country></address></affiliation></affiliationGroup><keywordGroup type="author"><keyword xml:id="mds25321-kwd-0001">dyskinesia</keyword><keyword xml:id="mds25321-kwd-0002">Parkinson's disease</keyword><keyword xml:id="mds25321-kwd-0003">rating scales</keyword><keyword xml:id="mds25321-kwd-0004">clinimetrics</keyword><keyword xml:id="mds25321-kwd-0005">amantadine</keyword><keyword xml:id="mds25321-kwd-0006">clinical trials</keyword></keywordGroup><supportingInformation><p>Additional Supporting Information may be found in the online version of this article.</p><supportingInfoItem><mediaResource alt="application" href="urn-x:wiley:08853185:media:mds25321:mds25321-sup-0001-suppinfo"></mediaResource><caption>Supplementary Information</caption></supportingInfoItem></supportingInformation><abstractGroup><abstract type="main"><title type="main">ABSTRACT</title><p>Numerous scales assess dyskinesia in Parkinson's disease (<fc>PD</fc>), variably focusing on anatomical distribution, phenomenology, time, severity, and disability. No study has compared these scales and their relative ability to detect change related to an established treatment. We conducted a randomized placebo‐controlled trial of amantadine, assessing dyskinesia at baseline and at 4 and 8 weeks using the following scales: Unified Dyskinesia Rating Scale (<fc>UDysRS</fc>), Lang‐Fahn Activities of Daily Living Dyskinesia Rating Scale (<fc>LF</fc>), 26‐Item Parkinson's Disease Dyskinesia scale (<fc>PDD</fc>‐26), patient diaries, modified Abnormal Involuntary Movements Scale (<fc>AIMS</fc>), Rush Dyskinesia Rating Scale (<fc>RDRS</fc>), dyskinesia items from the <i>Movement</i> Disorder Society–sponsored revision of the Unified Parkinson's Disease Rating Scale (<fc>MDS</fc>‐<fc>UPDRS</fc>), and Clinical Global Impression (severity and change: <fc>CGI</fc>‐S, <fc>CGI‐C</fc>). Scale order was randomized at each visit, but raters were aware of each scale as it was administered. Sensitivity to treatment was assessed using effect size. Sixty‐one randomized dyskinetic <fc>PD</fc> subjects (31 amantadine, 30 placebo) completed the study. Four of the 8 scales (<fc>CGI‐C</fc>, <fc>LF</fc>, <fc>PDD‐26</fc>, and <fc>UDysRS</fc>) detected a significant treatment. The <fc>UDysRS</fc> Total Score showed the highest effect size (η<sup>2</sup> = 0.138) for detecting treatment‐related change, with all other scales having effect sizes < 0.1. No scale was resistant to placebo effects. This study resolves 2 major issues useful for future testing of new antidyskinesia treatments: among tested scales, the <fc>UDysRS</fc>, having both subjective and objective dyskinesia ratings, is superior for detecting treatment effects; and the magnitude of the <fc>UDysRS</fc> effect size from amantadine sets a clear standard for comparison for new agents. © 2012 <i>Movement</i> Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="mds25321-note-0001" numbered="no"><p>The <i>Movement</i> Disorder Society owns the RDRS and the UDysRS with its training materials. Use of these scales for individual patient care purposes is free of charge without needed permission from the MDS. For studies or contracts, access and training fees may apply and can be acquired by contact with the MDS (<email>jwolf@movementdisorders.org</email>).</p></note><note xml:id="mds25321-note-0002" numbered="no"><p><b>Funding agencies:</b> The trial was sponsored by a grant from the Michael J. Fox Foundation for Parkinson's Research. The Rush Movement Disorder Program is also supported by the Parkinson's Disease Foundation.</p></note><note xml:id="mds25321-note-0003" numbered="no"><p><b>Relevant conflicts of interest/financial disclosures:</b> Christopher G. Goetz, John G. Nutt, and Glenn T. Stebbins participated in the development of the UDysRS. Christopher G. Goetz and Glenn T. Stebbins participated in the development of the RDRS. Robert A. Hauser participated in the development of the dyskinesia diaries used in this study.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Which dyskinesia scale best detects treatment response?</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Dyskinesia Scale Detecting Treatment Response</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Which dyskinesia scale best detects treatment response?</title></titleInfo><name type="personal"><namePart type="given">Christopher G.</namePart><namePart type="family">Goetz</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurological Sciences, Rush University Medical Center, Illinois, Chicago, USA</affiliation><affiliation>E-mail: cgoetz@rush.edu</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Glenn T.</namePart><namePart type="family">Stebbins</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Neurological Sciences, Rush University Medical Center, Illinois, Chicago, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Kathryn A.</namePart><namePart type="family">Chung</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Oregon Health Sciences University and Portland VA Medical Center, Oregon, Portland, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Robert A.</namePart><namePart type="family">Hauser</namePart><namePart type="termsOfAddress">MD, MBA</namePart><affiliation>Department of Neurology, University of South Florida, Florida, Tampa, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Janis M.</namePart><namePart type="family">Miyasaki</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>The Edmond J. Safra Program in Parkinson's Disease, University of Toronto, Ontario, Toronto, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Anthony P.</namePart><namePart type="family">Nicholas</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, University of Alabama and Birmingham VA Medical Center, Alabama, Birmingham, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Werner</namePart><namePart type="family">Poewe</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Klaus</namePart><namePart type="family">Seppi</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Innsbruck Medical University, Innsbruck, Austria</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Olivier</namePart><namePart type="family">Rascol</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Clinical Investigation Center CIC9302 and Departments of Clinical Pharmacology and Neuroscience, INSERM, University Hospital of Toulouse and University of Toulouse III, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Mark A.</namePart><namePart type="family">Stacy</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Duke University, North Carolina, Durham, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">John G.</namePart><namePart type="family">Nutt</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, Oregon Health Sciences University and Portland VA Medical Center, Oregon, Portland, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Caroline M.</namePart><namePart type="family">Tanner</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Parkinson's Institute and Clinical Center, California, Sunnyvale, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alison</namePart><namePart type="family">Urkowitz</namePart><namePart type="termsOfAddress">MPA</namePart><affiliation>Michael J. Fox Foundation for Parkinson's Research, New York, New York City, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jean A.</namePart><namePart type="family">Jaglin</namePart><namePart type="termsOfAddress">RN</namePart><affiliation>Department of Neurological Sciences, Rush University Medical Center, Illinois, Chicago, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Song</namePart><namePart type="family">Ge</namePart><namePart type="termsOfAddress">MS</namePart><affiliation>Department of Neurological Sciences, Rush University Medical Center, Illinois, Chicago, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><dateIssued encoding="w3cdtf">2013-03</dateIssued><dateCreated encoding="w3cdtf">2012-12-04</dateCreated><dateCaptured encoding="w3cdtf">2012-09-04</dateCaptured><dateValid encoding="w3cdtf">2012-11-15</dateValid><copyrightDate encoding="w3cdtf">2013</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract>Numerous scales assess dyskinesia in Parkinson's disease (PD), variably focusing on anatomical distribution, phenomenology, time, severity, and disability. No study has compared these scales and their relative ability to detect change related to an established treatment. We conducted a randomized placebo‐controlled trial of amantadine, assessing dyskinesia at baseline and at 4 and 8 weeks using the following scales: Unified Dyskinesia Rating Scale (UDysRS), Lang‐Fahn Activities of Daily Living Dyskinesia Rating Scale (LF), 26‐Item Parkinson's Disease Dyskinesia scale (PDD‐26), patient diaries, modified Abnormal Involuntary Movements Scale (AIMS), Rush Dyskinesia Rating Scale (RDRS), dyskinesia items from the Movement Disorder Society–sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS), and Clinical Global Impression (severity and change: CGI‐S, CGI‐C). Scale order was randomized at each visit, but raters were aware of each scale as it was administered. Sensitivity to treatment was assessed using effect size. Sixty‐one randomized dyskinetic PD subjects (31 amantadine, 30 placebo) completed the study. Four of the 8 scales (CGI‐C, LF, PDD‐26, and UDysRS) detected a significant treatment. The UDysRS Total Score showed the highest effect size (η2 = 0.138) for detecting treatment‐related change, with all other scales having effect sizes < 0.1. No scale was resistant to placebo effects. This study resolves 2 major issues useful for future testing of new antidyskinesia treatments: among tested scales, the UDysRS, having both subjective and objective dyskinesia ratings, is superior for detecting treatment effects; and the magnitude of the UDysRS effect size from amantadine sets a clear standard for comparison for new agents. © 2012 Movement Disorder Society</abstract><subject><genre>keywords</genre><topic>dyskinesia</topic><topic>Parkinson's disease</topic><topic>rating scales</topic><topic>clinimetrics</topic><topic>amantadine</topic><topic>clinical trials</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov Disord.</title></titleInfo><genre type="journal">journal</genre><note type="content"> Additional Supporting Information may be found in the online version of this article.Supporting Info Item: Supplementary Information - </note><subject><genre>article-category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>28</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>341</start><end>346</end><total>6</total></extent></part></relatedItem><identifier type="istex">8C074267DAD4F0BE4E25A0574ABEF5255353838F</identifier><identifier type="DOI">10.1002/mds.25321</identifier><identifier type="ArticleID">MDS25321</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2012 Movement Disorder SocietyCopyright © 2012 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002694 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002694 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:8C074267DAD4F0BE4E25A0574ABEF5255353838F
|texte= Which dyskinesia scale best detects treatment response?
}}
| This area was generated with Dilib version V0.6.29. |  |